Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
Rhea-AI Summary
Monte Rosa Therapeutics (Nasdaq: GLUE) will present interim clinical results for the NEK7-directed molecular glue degrader MRT-8102 on Jan 7, 2026 at 8:00 a.m. ET. The presentation will highlight interim data from the ongoing Phase 1 study, including the Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk.
The event will be available via live conference call and webcast through the company’s Events & Presentations page at ir.monterosatx.com, with an archived webcast accessible for 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – GLUE
On the day this news was published, GLUE gained 11.18%, reflecting a significant positive market reaction. Argus tracked a peak move of +81.2% during that session. Our momentum scanner triggered 41 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $164M to the company's valuation, bringing the market cap to $1.63B at that time. Trading volume was exceptionally heavy at 11.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GLUE was down 5.94% while peers were mixed: ENGN -1.91%, CTNM -11.66%, DSGN -4.19%, FDMT -0.41%, and DRTS up 5.67%, suggesting a stock-specific move rather than a uniform sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 16 | Clinical data update | Positive | +13.4% | Interim Phase 1/2 MRT-2359 combo data showed strong activity and control rates. |
| Dec 15 | Clinical update scheduling | Neutral | +0.9% | Announcement of webcast to present updated MRT-2359 Phase 1/2 interim results. |
| Nov 06 | Earnings and partnership | Positive | +5.7% | Q3 2025 results with Novartis deal, strong cash and multiple advancing programs. |
| Nov 03 | Investor conferences | Neutral | -6.1% | Participation in several investor conferences without new clinical or financial data. |
| Oct 24 | Preclinical data | Positive | +7.3% | Preclinical MRT-6160 data showing broad activity and disease reduction signals. |
Positive clinical and financial milestones have generally aligned with upside moves, while neutral conference-related news has coincided with at least one notable pullback.
Over the past months, Monte Rosa has reported multiple milestones. On Dec 16, 2025, compelling interim Phase 1/2 MRT-2359 combination data coincided with a 13.43% gain. Updated MRT-2359 results scheduling on Dec 15, 2025 saw a modest 0.86% rise. Q3 2025 results on Nov 6 with a Novartis collaboration and cash runway through 2028 aligned with a 5.69% increase. Preclinical MRT-6160 data on Oct 24 produced a 7.32% move, while investor conference participation on Nov 3 preceded a -6.07% decline.
Market Pulse Summary
The stock surged +11.2% in the session following this news. A strong positive reaction aligns with the pattern seen when Monte Rosa reported earlier clinical and financial milestones, where several updates coincided with moves above 5%. However, past trading also showed that non-data events, like conference participation, did not always sustain momentum. Investors evaluating a surge around interim MRT-8102 Phase 1 data may consider how incremental the results are versus prior expectations and remain mindful that enthusiasm can fade if subsequent readouts or strategic updates lag.
Key Terms
molecular glue degrader medical
nek7-directed medical
crp medical
AI-generated analysis. Not financial advice.
Conference call and webcast to be held at 8 a.m. ET on January 7, 2026
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Wednesday, January 7, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1 study of the NEK7-directed MGD MRT-8102, including interim data from the ongoing Part 3 CRP proof-of-concept cohort in subjects with elevated cardiovascular disease risk.
A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of the webcast will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
When will Monte Rosa Therapeutics (GLUE) present interim MRT-8102 Phase 1 results?
What data will Monte Rosa share about MRT-8102 in the Jan 7, 2026 presentation?
How can investors access the Monte Rosa webcast for GLUE’s MRT-8102 update?
Will the MRT-8102 presentation webcast be available after the live event?
What is the focus of the Part 3 CRP cohort mentioned for MRT-8102?
